Guided Therapeutics, Inc. (GTHP)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Guided Therapeutics, Inc. (GTHP) with AI Score 44/100 (Weak). Guided Therapeutics, Inc. is a medical technology company focused on developing and commercializing the LuViva advanced cervical scan. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Guided Therapeutics, Inc. (GTHP) Healthcare & Pipeline Overview
Guided Therapeutics, Inc. is a medical device company specializing in non-invasive cervical cancer detection with its LuViva device. Targeting point-of-care diagnostics, the company operates in a competitive medical device market, facing challenges in commercialization and market adoption within the broader healthcare sector.
Investment Thesis
Guided Therapeutics, Inc. presents a high-risk, high-reward investment profile. The company's LuViva device targets a critical need for improved cervical cancer screening, offering a potential alternative to traditional methods. However, the company's financial performance, with a negative profit margin of -1478.7% and reliance on OTC markets, raises concerns about its long-term viability. The success of Guided Therapeutics hinges on successful commercialization of LuViva, regulatory approvals, and market adoption. Investors should carefully consider the company's limited resources, competitive landscape, and dependence on future funding to sustain operations. The company's beta of 0.56 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.02 billion indicates a micro-cap company with limited financial resources.
- Negative P/E ratio of -8.69 reflects the company's current lack of profitability.
- Gross margin of 33.7% suggests potential for profitability if sales volume increases and operating expenses are managed effectively.
- Profit margin of -1478.7% highlights significant losses and the need for improved cost management.
- The company operates with only 4 employees, indicating a lean organizational structure and reliance on external partnerships.
Competitors & Peers
Strengths
- Non-invasive cervical cancer detection.
- Point-of-care diagnostic capability.
- Proprietary LuViva technology.
- Potential for improved patient compliance.
Weaknesses
- Limited financial resources.
- Negative profit margin.
- Small number of employees.
- Reliance on OTC markets.
Catalysts
- Upcoming: Potential regulatory approvals for LuViva in new geographic regions.
- Upcoming: Strategic partnerships with healthcare providers and distributors.
- Ongoing: Continued commercialization efforts for LuViva in the United States.
- Ongoing: Research and development of new features for the LuViva device.
- Ongoing: Direct-to-consumer marketing campaigns to raise awareness of LuViva.
Risks
- Potential: Competition from established screening methods and alternative technologies.
- Potential: Regulatory hurdles and delays in obtaining approvals.
- Ongoing: Limited financial resources and dependence on future funding.
- Ongoing: Negative profit margin and need for improved cost management.
- Potential: Limited market adoption and resistance to new technologies.
Growth Opportunities
- Market Expansion: Guided Therapeutics has the opportunity to expand its market reach beyond the United States by obtaining regulatory approvals in other countries. The global cervical cancer screening market presents a significant opportunity for growth, particularly in developing countries with limited access to traditional screening methods. Successful international expansion could significantly increase LuViva sales and revenue.
- Strategic Partnerships: Collaborating with established healthcare providers and distributors can accelerate the adoption of LuViva. Partnering with large hospital networks, clinics, and women's health organizations can provide access to a wider patient base and enhance the credibility of the device. Strategic alliances can also facilitate market entry into new geographic regions.
- Product Development: Enhancing the capabilities of the LuViva device through further research and development can improve its accuracy and expand its applications. Developing new features, such as integration with electronic health records or improved data analytics, can increase the value proposition of the device and attract more customers. Continuous innovation is essential to maintain a competitive edge in the medical device industry.
- Direct-to-Consumer Marketing: Implementing a direct-to-consumer marketing strategy can raise awareness of LuViva and drive demand for the device. Educating women about the benefits of non-invasive cervical cancer screening can increase patient interest and encourage them to discuss LuViva with their healthcare providers. Effective marketing campaigns can also help to overcome resistance to new technologies.
- Point-of-Care Diagnostics: Capitalizing on the growing trend towards point-of-care diagnostics can drive adoption of LuViva. Point-of-care testing offers convenience and faster results, which can improve patient compliance and reduce the time to diagnosis. As healthcare systems increasingly prioritize efficiency and patient-centered care, the demand for point-of-care diagnostic solutions is expected to grow.
Opportunities
- Market expansion into new geographic regions.
- Strategic partnerships with healthcare providers.
- Product development and innovation.
- Direct-to-consumer marketing.
Threats
- Competition from established screening methods.
- Regulatory hurdles.
- Limited market adoption.
- Dependence on future funding.
Competitive Advantages
- Proprietary LuViva technology.
- Non-invasive cervical cancer detection method.
- Point-of-care diagnostic capability.
- Potential for improved patient compliance.
About GTHP
Guided Therapeutics, Inc., originally incorporated as SpectRx, Inc. in 1992, rebranded in 2008 to focus on medical device development. The company's core product is LuViva, a non-invasive device designed for the detection of cervical cancers and precancers. LuViva employs optical scanning technology to analyze reflected and fluorescent light from the cervix, providing a point-of-care diagnostic tool. The company aims to offer a painless and non-invasive alternative to traditional methods like Pap smears and biopsies. Guided Therapeutics operates primarily in the United States, seeking to expand its market reach through strategic partnerships and regulatory approvals in other regions. The company's business model centers on the commercialization and distribution of LuViva to healthcare providers, including gynecologists and clinics. Guided Therapeutics faces competition from established diagnostic companies and alternative screening methods. The company is based in Norcross, Georgia, and is led by CEO Mark L. Faupel, who manages a small team of four employees.
What They Do
- Develops and commercializes medical devices.
- Focuses on cervical cancer detection technology.
- Offers LuViva, a non-invasive cervical scan.
- Provides point-of-care diagnostic solutions.
- Aims to improve early detection of cervical cancers and precancers.
- Utilizes optical scanning technology for cervical analysis.
Business Model
- Sells LuViva devices to healthcare providers.
- Generates revenue from device sales and related services.
- Targets gynecologists, clinics, and hospitals.
- Focuses on point-of-care diagnostics market.
Industry Context
Guided Therapeutics operates within the medical device industry, specifically targeting the cervical cancer screening market. This market is characterized by established screening methods like Pap smears and HPV tests, as well as emerging technologies. The competitive landscape includes companies offering alternative diagnostic solutions and established players in women's health. The global cervical cancer screening market is expected to grow, driven by increasing awareness and the need for more effective and accessible screening methods. Guided Therapeutics aims to capture a share of this market with its LuViva device, offering a point-of-care, non-invasive option.
Key Customers
- Gynecologists
- Hospitals
- Clinics
- Women's health centers
Financials
Chart & Info
Guided Therapeutics, Inc. (GTHP) stock price: Price data unavailable
Latest News
-
Guided Therapeutics (OTCMKTS:GTHP) Shares Down 12.7% – Time to Sell?
defenseworld.net · Mar 10, 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GTHP.
Price Targets
Wall Street price target analysis for GTHP.
MoonshotScore
What does this score mean?
The MoonshotScore rates GTHP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Mark L. Faupel
CEO
Mark L. Faupel serves as the CEO of Guided Therapeutics, Inc. His background includes experience in managing and leading small teams within the medical technology sector. He is responsible for overseeing the company's strategic direction, product development, and commercialization efforts. His leadership is focused on driving the adoption of the LuViva device and expanding the company's market presence. He manages a team of 4 employees.
Track Record: Under Mark L. Faupel's leadership, Guided Therapeutics has focused on the commercialization of the LuViva device. His tenure has involved navigating regulatory challenges and seeking strategic partnerships to expand market reach. Key milestones include securing funding to support ongoing operations and advancing the development of new features for the LuViva device. He is responsible for the overall financial and operational performance of the company.
GTHP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Guided Therapeutics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of regulatory oversight and transparency compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Lower trading volume and liquidity.
- Higher price volatility.
- Increased risk of fraud or manipulation.
- Potential for delisting or suspension of trading.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Review the company's risk factors and potential liabilities.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investing.
- The company has a functioning website and contact information.
- The company has a CEO and management team.
- The company has a registered business address.
- The company has a product (LuViva) in development and commercialization phase.
- The company was incorporated in 1992.
What Investors Ask About Guided Therapeutics, Inc. (GTHP)
What does Guided Therapeutics, Inc. do?
Guided Therapeutics, Inc. is a medical technology company focused on developing and commercializing the LuViva advanced cervical scan. LuViva is a non-invasive point-of-care device designed for the early detection of cervical cancers and precancers. The device uses optical scanning technology to analyze reflected and fluorescent light from the cervix, providing a real-time assessment. Guided Therapeutics aims to offer a more convenient and patient-friendly alternative to traditional screening methods like Pap smears and biopsies.
What do analysts say about GTHP stock?
There is currently no available analyst coverage for GTHP stock. Given its OTC listing and micro-cap status, Guided Therapeutics may not attract significant attention from major research firms. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making an investment decision. Key valuation metrics, such as revenue growth, profitability, and cash flow, should be carefully analyzed.
What are the main risks for GTHP?
Guided Therapeutics faces several significant risks. The company's limited financial resources and negative profit margin raise concerns about its ability to sustain operations and fund future growth. Competition from established screening methods and alternative technologies poses a challenge to market adoption of LuViva. Regulatory hurdles and delays in obtaining approvals can also impact the company's timeline and financial performance. Furthermore, the company's reliance on OTC markets increases the risk of illiquidity and price volatility.
What revenue streams does Guided Therapeutics, Inc. have in healthcare?
Guided Therapeutics, Inc.'s primary revenue stream is currently derived from the sales of its LuViva device to healthcare providers, including gynecologists, clinics, and hospitals. The company generates revenue from the initial sale of the device and potentially from ongoing service and maintenance contracts. As the company expands its market reach and increases adoption of LuViva, it may explore additional revenue streams, such as consumables or subscription-based services. However, the company's current revenue model is heavily reliant on device sales.
How does Guided Therapeutics, Inc. manage patent expiration risks?
Guided Therapeutics, Inc. relies on patents to protect its proprietary LuViva technology. While the provided data does not give specific details on patent expiration dates, the company must actively manage its intellectual property portfolio to mitigate the risks associated with patent expirations. This includes seeking new patents for innovations and improvements to the LuViva device, as well as developing strategies to extend the life cycle of its existing patents. The company should also monitor the competitive landscape for potential patent infringement and take appropriate legal action to protect its intellectual property rights.
What are the key factors to evaluate for GTHP?
Guided Therapeutics, Inc. (GTHP) currently holds an AI score of 44/100, indicating low score. Key strength: Non-invasive cervical cancer detection.. Primary risk to monitor: Potential: Competition from established screening methods and alternative technologies.. This is not financial advice.
How frequently does GTHP data refresh on this page?
GTHP prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GTHP's recent stock price performance?
Recent price movement in Guided Therapeutics, Inc. (GTHP) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Non-invasive cervical cancer detection.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for comprehensive analysis.
- OTC market carries higher risks than major exchanges.
- AI analysis pending for GTHP.